Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ripasudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 13/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 12/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 4/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | MARK3 | P27448 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 2/20 | 1.00 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | MAP2K3 | P46734 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 1/20 | 1.00 |
| ▸ | PKN1 | Q16512 | 1/20 | 1.00 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 1.00 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 4/20 | 0.81 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.81 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ripasudil SCHEMBL29356679 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL5339449 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL4897040 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL4897028 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL3081946 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL29404703 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL31419771 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL20557243 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL22497129 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 | |
| Ripasudil SCHEMBL29365413 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCDPLK4MARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | claimed |
| US-20220047585-A1 | PREVENTING OR TREATING AGENT FOR GLAUCOMA | KOWA CO., LTD. (JP) | 2022-02-17 | — | — | US | claimed |
| CN-106794186-B | Pharmaceutical preparation | 兴和株式会社 | 2020-06-05 | — | — | CN | claimed |
| CN-106714806-B | Aqueous composition | 兴和株式会社 | 2020-03-03 | — | — | CN | claimed |
| US-20190328730-A1 | PREVENTING OR TREATING AGENT FOR GLAUCOMA | KOWA CO., LTD. (JP) | 2019-10-31 | — | — | US | claimed |
| US-9844556-B2 | Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery | MEGUMI HONJO (JP) | 2017-12-19 | — | — | US | claimed |
| US-20170020887-A1 | PREVENTIVE/THERAPEUTIC METHOD AND PREVENTIVE/THERAPEUTIC AGENT FOR COMPLICATIONS AFTER CATARACT SURGERY | Honjo, Megumi (JP) | 2017-01-26 | — | — | US | claimed |
| US-20130177655-A1 | PREVENTING OR TREATING AGENT FOR GLAUCOMA | KOWA CO., LTD. (JP) | 2013-07-11 | — | — | US | claimed |
| US-20100233287-A1 | PREVENTING OR TREATING AGENT FOR GLAUCOMA | KOWA CO., LTD. (JP) | 2010-09-16 | — | — | US | claimed |
| EP-1818059-B1 | PREVENTIVE OR THERAPEUTIC AGENT FOR GLAUCOMA | KOWA CO (JP) | 2008-12-03 | — | — | EP | claimed |
| EP-1818059-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR GLAUCOMA | Kowa Company, Ltd. (JP) | 2007-08-15 | — | — | EP | claimed |
| US-20060142270-A1 | Preventing or treating agent for glaucoma | KOWA CO., LTD. (JP) | 2006-06-29 | — | — | US | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12390420-B1 | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof | BRYET US, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12281308-B2 | Inhibition of protein kinases to treat Friedreich ataxia | UNIVERSITY OF MASSACHUSETTS (US) | 2025-04-22 | — | — | US | disclosed |
| EP-1818059-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR GLAUCOMA | Kowa Company, Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006068208-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR GLAUCOMA | KOWA CO., LTD. (JP) | 2006-06-29 | — | — | WO | disclosed |
| US-20060142270-A1 | Preventing or treating agent for glaucoma | KOWA CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| US-20060142270-A1 | Preventing or treating agent for glaucoma | KOWA CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390420-B1 | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof | MSN, CD47, CTTN | ROCK2 894/4885ROCK1 1117/4885PRKCD 3361/4885 |
| US-20170020887-A1 | PREVENTIVE/THERAPEUTIC METHOD AND PREVENTIVE/THERAPEUTIC AGENT FOR COMPLICATIONS AFTER CATARACT SURGERY | CRYZ, SIRT5, FOXK1 | ROCK2 20/4885ROCK1 14/4885PRKCD 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.